Promising combo targets tough esophageal cancer in small trial
NCT ID NCT07188103
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether a drug called ivonescimab, given together with a short course of targeted radiation, can help people with advanced esophageal cancer that has worsened after first treatment. The study will enroll 37 adults and track how long they live without the cancer growing, as well as side effects. It is a single-center, single-arm study, meaning everyone gets the same treatment and there is no placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivonescimab (a monoclonal antibody) combined with short-course hypofractionated radiotherapy
- What this could lead to
- If successful, this could offer a new second-line treatment option for people with advanced esophageal cancer that has stopped responding to initial therapy.
- What could go wrong
- This is a small, early-phase trial with only 37 participants and no comparison group, so results may not be definitive. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincal Hospital
RECRUITINGHefei, Anhui, 230000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads